TAVR Available for Patients with Intermediate Risk 

The Food and Drug Administration (FDA) recently approved the TAVR (Transcatheter Aortic Valve Replacement) procedure for intermediate risk patients. This minimally invasive, life-saving procedure can now be performed on patients with aortic stenosis who are considered intermediate risk for traditional heart surgery. This is very exciting news for our team at Oklahoma Heart Institute considering the fact that this procedure was originally approved for high-risk patients only. Watch our video below to learn more from our structural heart and TAVR team as to why this recent approval is so important!